Amneal Pharmaceuticals (AMRX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec5

Amneal Pharmaceuticals' CREXONT® Shows Positive Mid-Stage Results in Parkinson's Disease Study

13:01

Dec2

Amneal Pharmaceuticals Inc. Secures FDA Approval for Respiratory Product

13:00

Dec1

Amneal Pharmaceuticals Inc. Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05% Generic Drug

21:01

Oct31

Sulewski reiterates hold rating on Amneal Pharmaceuticals

12:27

Oct30

Amneal Pharmaceuticals released FY2025 Q3 earnings on October 30 Pre-Market EST, actual revenue USD 784.51 M (forecast USD 773.81 M), actual EPS USD 0.0075 (forecast USD 0.02)

13:30

Amneal Pharmaceuticals released FY2025 9 Months Earnings on October 30 Pre-Market (EST), actual revenue USD 2.204 B, actual EPS USD 0.1167

13:30

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 784.51 M, Net Income 2.369 M, EPS 0.0075

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 724.51 M, Net Income 22.42 M, EPS 0.07

May2

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 695.42 M, Net Income 12.2 M, EPS 0.0392

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change